Navigation Links
Researchers discover molecule in immune system that could help treat dangerous skin cancer
Date:7/8/2012

BOSTON, MAResearchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.

Their findings will be published online in the July 8, 2012 issue of Nature Medicine.

After observing mice without genes responsible for development of an immune cell called T helper cell 17 (TH17), researchers found that these mice had significant resistance to melanoma tumor growth, suggesting that blockade of the TH17 cell pathway favored tumor inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.

"These were unexpected results, which led us to examine a possible contribution of interleukin-9 to cancer growth suppression." said Purwar.

The researchers next treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. They saw that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumor effect of TH9 cells.

Moreover, the researchers were able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory T cells and memory T cells in peripheral blood mononuclear cells. In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in human cancer therapy.

"Immunotherapy of cancer is coming of age, and there have been exciting recent results in patients with melanoma treated with drugs that stimulate the immune system," said Kupper. "We hope that our results will also translate to the treatment of melanoma patients, but much work still needs to be done."

According to the researchers, other cell-signaling molecules have been used in treating melanoma; however, this study is the first to investigate the role of interleukin-9 in melanoma tumor immunity.

Melanoma is the most dangerous form of skin cancer. The National Cancer Institute estimates that in 2012, there will be more than 76,000 new cases of melanoma in the United States and 9,180 deaths. Melanoma is curable if recognized and treated early.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related biology news :

1. Researchers moving towards ending threat of West Nile virus
2. NOAA researchers see dramatic decline of endangered white abalone
3. BESC researchers tap into genetic reservoir of heat-loving bacteria
4. Researchers and communities at risk join forces in volcano study
5. Penn researchers improve living tissues with 3-D printed vascular networks made from sugar
6. BUSM researchers identify role of FOXO1 gene in Parkinsons disease
7. How sweet it is: Tomato researchers discover link between ripening, color and taste
8. Researchers discover potential explanation for why a diet high in DHA improves memory
9. Rice researchers develop paintable battery
10. UMass Medical School researchers discover a new role for RNAi
11. Researchers develop new method for analyzing cell function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Research and Markets ... has announced the addition of the "Implantable Biomaterials ... report to their offering. Report Highlights: ... detailed analysis on current and future market trends to identify the investment ... as the base numbers Key market trends across the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is proud ... 21 CFR Part 11-compliant email client designed to provide product vigilance departments with ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  ArmaGen, ... Mathias Schmidt , Ph.D., as chief executive officer, ... of directors. Dr. Schmidt brings to ArmaGen more than ... the research and development of biotherapeutics and pharmaceuticals. ... executive with the diverse experience and skillset necessary ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
Breaking Biology Technology: